» Articles » PMID: 14572927

Predictive Genetic Test Decisions for Huntington's Disease: Context, Appraisal and New Moral Imperatives

Overview
Journal Soc Sci Med
Date 2003 Oct 24
PMID 14572927
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Predictive testing is one of the new genetic technologies which, in conjunction with developing fields such as pharmacogenomics, promises many benefits for preventive and population health. Understanding how individuals appraise and make genetic test decisions is increasingly relevant as the technology expands. "Lay" understandings of genetic risk and test decision-making, located within holistic life frameworks including family or kin relationships, may vary considerably from clinical representations of these phenomena. The predictive test for Huntington's disease (HD), whilst specific to a single-gene, serious, mature-onset but currently untreatable disorder, is regarded as a model in this context. This paper reports upon a qualitative Australian study which investigated predictive test decision-making by individuals at risk for HD, the contexts of their decisions and the appraisals which underpinned them. In-depth interviews were conducted in Australia with 16 individuals at 50% risk for HD, with variation across testing decisions, gender, age and selected characteristics. Findings suggested predictive testing was regarded as a significant life decision with important implications for self and others, while the right "not to know" genetic status was staunchly and unanimously defended. Multiple contexts of reference were identified within which test decisions were located, including intra- and inter-personal frameworks, family history and experience of HD, and temporality. Participants used two main criteria in appraising test options: perceived value of, or need for the test information, for self and/or significant others, and degree to which such information could be tolerated and managed, short and long-term, by self and/or others. Selected moral and ethical considerations involved in decision-making are examined, as well as the clinical and socio-political contexts in which predictive testing is located. The paper argues that psychosocial vulnerabilities generated by the availability of testing technologies and exacerbated by policy imperatives towards individual responsibility and self-governance should be addressed at broader societal levels.

Citing Articles

Genetic testing for monogenic forms of motor neuron disease/amyotrophic lateral sclerosis in unaffected family members.

Howard J, Chaouch A, Douglas A, MacLeod R, Roggenbuck J, McNeill A Eur J Hum Genet. 2024; 33(1):7-13.

PMID: 39501102 PMC: 11711763. DOI: 10.1038/s41431-024-01718-4.


Experiences of predictive genetic testing in inherited motor neuron disease: Findings from a qualitative interview study.

Howard J, Forrest Keenan K, Mazanderani F, Turner M, Locock L J Genet Couns. 2024; 34(1):e1904.

PMID: 38628040 PMC: 11735176. DOI: 10.1002/jgc4.1904.


Nipping Diseases in the Bud? Ethical and Social Considerations of the Concept of 'Disease Interception'.

Narchi J, Winkler E Public Health Ethics. 2021; 14(1):100-108.

PMID: 34234842 PMC: 8254639. DOI: 10.1093/phe/phaa036.


Perceptions of the impact of chorea on health-related quality of life in Huntington disease (HD): A qualitative analysis of individuals across the HD spectrum, family members, and clinicians.

Sherman C, Iyer R, Abler V, Antonelli A, Carlozzi N Neuropsychol Rehabil. 2019; 30(6):1150-1168.

PMID: 30849283 PMC: 7685000. DOI: 10.1080/09602011.2018.1564675.


The Changing Age of Individuals Seeking Presymptomatic Genetic Testing for Huntington Disease.

Holman M, Quillin J, York T, Testa C, Rosen A, Norris V J Genet Couns. 2018; 27(5):1157-1166.

PMID: 29460111 DOI: 10.1007/s10897-018-0233-9.